This doesn’t make much sense to me. The company has to recoup that cost of R & D, which currently happens via a higher price on new drugs. If generic producers can simply piggyback on R & D immediately, the developing company can’t charge a higher price for new drugs. And the idea that the company would then dump a bunch more money into new therapies that in return yield no profit is wishful thinking.